Drug Trial Radar · NCT02908906
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
234
Actual
Start
Nov 21, 2016
Primary completion
Nov 17, 2023
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Primary purpose of this study is to identify the recommended Phase 2 dose \[RP2D(s)\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4.
Conditions
- Neoplasms
Interventions
JNJ-63723283Drug
JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Frequency and Severity of Dose-Limiting Toxicity (DLT)Time frame: Up to 2 years 6 months
- Part 2: Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Subjects With Selected Advanced Solid TumorsTime frame: Up to 2 years 6 months
- Parts 3 and 4: Area Under the Serum Concentration Versus Time Curve from Time Zero to Dosing Interval (AUC [0-tau])Time frame: Up to 2 years 6 months
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
St Louis, Missouri
Site not named
Pittsburgh, Pennsylvania
Site not named
Chisinau, Moldova
Site not named
Bialystok, Poland
Site not named
Warsaw, Poland
Site not named
Moscow, Russia
Site not named
Pyatigorsk, Russia
Site not named
Saint Petersburg, Russia
Site not named
Badalona, Spain
Site not named
Barcelona, Spain
Site not named
Madrid, Spain
Site not named
Málaga, Spain
Site not named
Pamplona, Spain
Site not named
Seville, Spain
Site not named
Valencia, Spain
Site not named
Gothenburg, Sweden
Site not named
Glasgow, United Kingdom
Site not named
London, United Kingdom
Site not named
Manchester, United Kingdom
Site not named
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.